Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
Peter SchmidJavier CortesRebecca DentLajos PusztaiHeather McArthurSherko KümmelJonas BerghCarsten DenkertYeon Hee ParkRina HuiNadia HarbeckMasato TakahashiMichael UntchPeter A FaschingFatima CardosoJay AndersenDebra PattMichael DansoMarta FerreiraMarie-Ange Mouret-ReynierSeock-Ah ImJin-Hee AhnMaria GionSally Baron-HayJean-François BoileauYu DingKonstantinos TryfonidisGursel AktanVassiliki KarantzaJoyce O'Shaughnessynull nullPublished in: The New England journal of medicine (2022)
In patients with early triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab after surgery, resulted in significantly longer event-free survival than neoadjuvant chemotherapy alone. (Funded by Merck Sharp and Dohme, a subsidiary of Merck; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.).